Bicara Therapeutics Inc.
BCAXNasdaq
$27.76
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +157.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.1B
P/E
—
P/S
—
P/B
3.3
EV/EBITDA
—
PEG
—
FCF Yield
-6.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$157.3M
Free Cash Flow (TTM)
-$116.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-30.6%
ROIC
—
Debt / Equity
—
Net Cash
$539.8M
Return 1Y
+138.3%
Company profile
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We were incorporated under the laws of the State of Delaware on December 12, 2018 under the name “Bicara Therapeutics Inc.” Our principal corporate office is located at 116 Huntington Avenue, Suite 703, Boston, MA 02116. We have one subsidiary, Bicara Securities Corporation, formed in October 2023 under the laws of the Commonwealth of Massachusetts.
- CEO
- Claire Mazumdar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- www.bicara.com
Management & directors
- Mazumdar ClaireChief Executive Officer
- Cohlhepp RyanPresident and COO
- Hyep IvanChief Financial Officer
- Raben DavidChief Medical Officer
- Meisner LaraChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
BCAX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.93↑ +36.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$39.9M | -$82.4M | -$155.6M |
| Net income | -$52.0M | -$68.0M | -$137.9M |
| Diluted EPS | -$89.61 | -$4.05 | -$2.52 |
| Operating cash flow | -$45.6M | -$74.8M | -$106.8M |
| Free cash flow | -$46.2M | -$74.8M | -$107.1M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.8M | -$20.6M | -$26.6M | -$41.8M | -$32.0M | -$40.7M | -$41.1M | -$60.2M |
| Net income | -$17.0M | -$17.5M | -$21.0M | -$36.8M | -$27.4M | -$36.3M | -$37.4M | -$56.2M |
| Diluted EPS | -$19.01 | -$1.60 | $35.50 | -$0.68 | -$0.50 | -$0.67 | -$0.67 | -$0.93 |
| Operating cash flow | -$12.9M | -$17.2M | -$30.0M | -$28.1M | -$25.6M | -$29.2M | -$23.9M | -$37.5M |
| Free cash flow | -$12.9M | -$17.2M | -$30.1M | -$28.1M | -$25.6M | -$29.3M | -$24.1M | -$37.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 13, 2026
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Mazumdar Claire· Chief Executive Officer | Sale | 9,972 | $28.42 | $283,367.34 | filing |
| 2026-07-10 | Mazumdar Claire· Chief Executive Officer | Option exercise | 10,000 | $3.79 | $37,898.00 | filing |
| 2026-07-10 | Mazumdar Claire· Chief Executive Officer | Sale | 28 | $29.68 | $831.04 | filing |
| 2026-07-09 | Cohlhepp Ryan· President and COO | Sale | 536 | $29.00 | $15,544.00 | filing |
| 2026-07-08 | Cohlhepp Ryan· President and COO | Sale | 22,833 | $28.76 | $656,651.96 | filing |
| 2026-07-08 | Hyep Ivan· Chief Financial Officer | Sale | 22,757 | $28.60 | $650,895.71 | filing |
| 2026-07-08 | Hyep Ivan· Chief Financial Officer | Sale | 4,413 | $29.82 | $131,615.96 | filing |
| 2026-07-08 | Cohlhepp Ryan· President and COO | Sale | 4,306 | $29.80 | $128,302.01 | filing |
| 2026-07-08 | Cohlhepp Ryan· President and COO | Option exercise | 18,750 | $3.79 | $71,058.75 | filing |
| 2026-07-08 | Hyep Ivan· Chief Financial Officer | Option exercise | 12,500 | $3.79 | $47,372.50 | filing |
| 2026-07-08 | Cohlhepp Ryan· President and COO | Sale | 1,075 | $30.35 | $32,631.52 | filing |
| 2026-07-08 | Hyep Ivan· Chief Financial Officer | Sale | 830 | $30.31 | $25,160.29 | filing |
| 2026-05-21 | Hyep Ivan· Chief Financial Officer | Sale | 9,200 | $20.42 | $187,883.32 | filing |
| 2026-05-21 | Hyep Ivan· Chief Financial Officer | Option exercise | 9,200 | $3.79 | $34,866.16 | filing |
| 2026-05-18 | Mazumdar Claire· Chief Executive Officer | Sale | 12,022 | $19.96 | $239,981.96 | filing |
| 2026-05-18 | Mazumdar Claire· Chief Executive Officer | Sale | 2,978 | $20.35 | $60,596.64 | filing |
| 2026-05-18 | Mazumdar Claire· Chief Executive Officer | Option exercise | 15,000 | $3.79 | $56,847.00 | filing |
| 2026-05-15 | Cohlhepp Ryan· President and COO | Sale | 8,000 | $20.29 | $162,335.20 | filing |
| 2026-05-15 | Cohlhepp Ryan· President and COO | Sale | 4,500 | $20.29 | $91,313.55 | filing |
| 2026-05-15 | Cohlhepp Ryan· President and COO | Option exercise | 8,000 | $3.79 | $30,318.40 | filing |
| 2026-04-27 | Raben David· Chief Medical Officer | Sale | 5,500 | $22.88 | $125,830.10 | filing |
| 2026-04-27 | Raben David· Chief Medical Officer | Option exercise | 5,500 | $3.79 | $20,843.90 | filing |
| 2026-04-21 | Hyep Ivan· Chief Financial Officer | Sale | 9,200 | $23.00 | $211,613.80 | filing |
| 2026-04-21 | Hyep Ivan· Chief Financial Officer | Option exercise | 9,200 | $3.79 | $34,866.16 | filing |
| 2026-04-20 | Mazumdar Claire· Chief Executive Officer | Sale | 15,000 | $23.61 | $354,145.50 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.